Adare Pharma acquires oral formulations specialist Frontida BioPharm

The combined company intends to lead in the space of oral formulations, solving customers' complex formulation challenges

In line with its mission to transform drug delivery, Adare Pharma Solutions has acquired Frontida BioPharm — a vertically integrated CDMO focused on oral formulations.

Customers will now be able to tap into Adare's new capabilities such as high potency compound handling and packaging services.

Together, the combined company will offer an expanded suite of solutions for complex oral formulations, such as taste masking, controlled release, high potency formulation manufacturing, and bioavailability enhancement.

The addition of Frontida brings Adare’s manufacturing footprint to seven sites spanning the US, Italy and France, and expands its integrated, end-to-end offering to its partners.

Vivek Sharma, CEO of Adare who will lead the combined organisation, said the acquistion will bolster Adare's ability to solve complex formulation challenges for its customers.

In April last year, Adare acquired Kansas-based pharmaceutical technology company Orbis Biosciences, whose platforms create drug particles that can be dosed in oral liquid, injectable, and otic dosage forms.

ABOUT ADARE PHARMA SOLUTIONS

Adare Pharma Solutions is a global technology-driven CDMO providing product development through commercial manufacturing expertise focused on oral dosage forms for the Pharmaceutical industry.  Adare’s specialized technology platforms provide taste masking, controlled release, solubility enhancement, and patient-centric dosing solutions.  With a proven history in drug delivery, Adare has developed and manufactured more than 40 products sold by customers in more than 100 countries globally.